Evolus says not affected by recent Korean court ruling

Evolus issued the following statement: "Earlier today, the Seoul Central District Court ruled in favor of Medytox, Inc. related to a long-standing trade secret dispute between Medytox and Daewoong Pharmaceutical Co. The recent ruling by the Seoul Central District Court does not affect Evolus’ ability to have Jeuveau or Nuceiva manufactured and exported by Daewoong or to sell the products in any of its markets. As part of Evolus’ global settlement with Medytox in February 2021, the parties resolved all litigation between the two parties and specifically stated that any Korean litigation between Medytox and Daewoong would not affect the supply of Jeuveau or Nuceiva. The rights granted to Evolus under the settlement include the right to have Jeuveau and Nuceiva manufactured and exported by Daewoong to Evolus and for Evolus to continue to commercialize the product."